Young David 4
4 · Processa Pharmaceuticals, Inc. · Filed Oct 3, 2025
Insider Transaction Report
Form 4
Young David
DirectorPres. Research & Development
Transactions
- Award
Stock Options (Right to Buy)
2025-10-01+333,000→ 333,000 totalExercise: $0.20→ Common Stock (333,000 underlying) - Award
Restricted Stock Units
2025-10-01+111,000→ 111,000 totalExercise: $0.00→ Common Stock (111,000 underlying)
Footnotes (2)
- [F1]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028.
- [F2]Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.